May 2026 Content Release Notes Copied

Problem Groups

Updates

Curbside Connect with Dr. Yardley for HR+, HER2-, and Triple Negative patients is no longer available for scheduling in Breast Cancer.

Lab Analytes & Panels

Summary

There were 100 new panels created and 43 new analytes created for the MAY_26 release.

Additions

• 95% confidence interval
• % Free testosterone (dialysis), %
• Acetylcholine receptor Abs panel
• Allergic bronchopulmonary aspergillosis profile 1 panel
• Allergic bronchopulmonary aspergillosis profile 2 panel
• ANA homegenous titer
• ANA nuclear dot titer
• Anti-C1Q Ab, IgG (RDL) panel
• Anti-C1Q Ab, IgG (RDL), units
• Anti-cN-1A (NT5c1A) IBM (RDL) , units
• Anti-cN-1A (NT5c1A) IBM (RDL) panel
• Anti-PM/Scl-75 Ab (RDL), units
• Antibiotic recommendation panel
• Antibiotic recommendation pathogen
• Antibody screen, RBC with reflex to identification, titer, and antigen typing panel
• Autoimmune hepatitis diagnostic panel
• Azithromycin level panel
• B pertussis IgG/IgM Ab panel
• B-ALL MRD Flow Panel
• Bartonella henselae antibodies (IgG, IgM) with reflex to titers panel
• BCR-ABL1 gene rearrangement, quantitative, PCR
• Beta-glucosidase, leukocytes panel
• BKV DNA, quant PCR, urine, IU/mL
• Blastomyces dermatitidis Ab EIA panel
• Bordetella pertussis Ab, IgG panel
• Brucella Ab IgG panel
• Brucella Ab IgM panel
• Buprenorphine, screen and confirmation, urine panel
• C1 esterase inhibitor, functional, %mean normal
• Diff toxin B cytotoxin assay panel
• Diff toxin NAA, with reflex to toxins A+B, EIA panel
• Calcium, blood panel
• Calculated sodium, mmol/L
• Cannabinoids screen, blood. ng/mL
• Celiac antibodies tTG IgA, EMA IgA, total IgA With reflex to tTG IgG panel
• Chlamydia/Neisseria gonorrhoeae RNA, TMA with reflex to alternate target, urogenital panel
• Chlamydia/gonococcus/genital mycoplasma profile NAA, swab panel
• Chlamydia trachomatis RNA, TMA, rectal panel
• Clonoseq B-cell tracking (MRD)
• Complement and coagulation mediated TMA (aHUS) genetic analysis panel
• Cytochrome P450 3A4/3A5 genotyping panel
• Des-y-carboxy prothrombin (PIVKA) panel
• DHA, % by wt
• Dominant sequences (B-cell)
• DPA, % by wt
• Drug Screen 13 with reflex confirmation panel
• Enhanced liver fibrosis, ELF panel
• EPA+DPA+DHA, % by wt
• EPA, % by wt
• Etanercept and anti-etanercept Ab panel
• Ethambutol level panel
• Extended myositis specific antibody (MSA) panel
• Factor V inhibitor (bethesda) panel
• Factor XI inactivator assay, bethesda
• Fentanyl screen, blood, ng/mL
• Fibrillarin (U3 RNP) Ab
• Fluconazole serum or plasma panel
• GeneSeq connective tissue: ehlers-danlos syndrome panel
• Gentamicin trough panel
• HA Ab
• Hemoglobinopathy fractionation cascade panel
• Hemoglobinopathy w/ reflex to a-T panel
• Heparin anti-Xa lovenox panel
• Heparin-dependent platelet antibody (serotonin release assay) panel
• Hepatitis C virus (HCV) antibody with reflex to quantitative real-time PCR panel
• Hepatitis C Virus (HCV), quantitative, RNA PCR with reflex to genotyping panel
• Histoplasma galactomannan Ag urine panel
• HIV-1 genosure integrase panel
• HIV-1 genosure prime panel
• HIV-2 DNA/RNA PCR qual panel
• HMGCR Ab screen
• HSV type 1/2 mRNA, TMA panel
• IFE, SPEP, and kappa/lambda light chains panel
• Immunofixation and electrophoresis 24-hour urine panel
• Immunofixation, daratumumab-specific, serum panel
• Iron level panel
• Iron/transferrin/ferritin panel
• JAK2 Exon 12-15 mutation analysis by NGS panel
• JAK2 V617F mutation analysis, quantitative panel
• KS Ab
• Linoleic acid, % by wt
• Lyme Ab reflex IgG IgM panel
• Lymphocyte activity profile panel
• Lymphocyte subset panel 4
• MDA5 (CADM-140) Ab
• Mitosis panel interpretation
• Murine typhus abs IgG
• Mycoplasma/ureaplasma panel
• N-Telopeptide cross-link NTx urine panel
• NXP2 Ab
• OMEGA-3 total, % by wt
• OMEGA-6 total, % by wt
• Omega check panel
• Oncohost PROphet NSCLC panel
• Ova and parasites, concentrate and permanent smear panel
• Oxalate: creatinine ratio random urine panel
• Oxycodones, MS, WB/SP RFX – blood panel
• P155/140 Ab
• Patient fasting glucose question
• PM/SCL 100 Ab
• Rabies vaccine response end point titer panel
• Rabies vaccine response end point titer, IU/mL
• Red blood cell membrane evaluation panel
• Residual clonal cells per million nucleaed cells (B-cell)
• Rifampin panel
• SA-52 (Ro52) Ab, AU/mL
• SAE1 Ab
• SMITH/RNP (ENA) Ab, AU/mL
• Spotted fever group comment
• Stiff-person disorders profile panel
• SureSwab advanced vaginitis, TMA panel
• SureSwab panel
• Syphilis: treponemal antibodies w/ reflex to RPR and RPR titer, reverse screening panel
• T-spot TB panel
• Tempus BRCAplus addendum report panel
• Tempus BRCAplus amendment report panel
• Tempus BRCAplus report panel
• Testosterone free (dialysis)
• TIF1-gamma (155kDa) Ab
• Titanium panel
• Tobramycin trough panel
• Toxoplasma gondii Ab,IgM panel
• Tramadol confirmation panel
• Tramadol screen with confirmation, urine panel
• Trichomonas vaginalis RNA qualitative, TMA, males panel
• Trichomonas vaginalis, NAA panel
• Urine creatinine 24 hour panel
• Vaginitis panel
• Vitamin A and E panel
• Wound culture/aerobic and anaerobic, tissue panel
• ZO Ab

Medications

Additions

• [F-18]-FAPI-74 invest IV
• AZD5335 invest IV
• Bleximenib (JNJ-75276617) invest Oral
• Clairvee Oral
• CLSP-1025 invest IV
• D07001 (Gemcitabine Hydrochloride) invest Oral
• HWK-016 invest IV
• INR731 invest Oral
• LY4337713 invest IV
• Miscellaneous Supply
• Nanvuranlat invest IV
• Noctera Oral
• Ristela Oral
• Serenol Oral
• Thermella Oral
• WU-CART-007 invest IV

Updates

Medications	Updates
BNT327 invest IV	New SIG available: 1200 mg intravenously once 1500 mg intravenously once New Form available: 50 mg/mL solution
Cemiplimab-rwlc IV	New Maximum Single Dose available: ·       700 mg
KER-050 invest Subcutaneous	Updated Name to: Elritercept (TAK-226, KER-050) invest Subcutaneous Updated SIGs to: 0 mg/kg subcutaneously every 4 weeks; Prepare and administer per Pharmacy Manual instructions. The maximum volume per injection is 2.0 mL. If the total volume is > 2.0 mL, the volume should be divided between separate syringes for separate injections as e 0 mg/kg subcutaneously every 4 weeks; injections will be made under the skin (SC), into the abdomen but not within 5 cm of the navel 0 mg/kg subcutaneously once (as default SIG)
M9140 invest IV	Updated Name to: Precemtabart tocentecan (Precem-TcT; M9140) invest IV New Form available: 80 mg recon soln
Miracle Mouthwash (Benadryl elixir‑Hydrocortisone‑Nystatin susp‑Viscous Lidocaine‑Maalox or Mylanta)	Updated Name to: Miracle Mouthwash (Diphen-HC-Nyst susp-Lido visc-Maalox/Mylanta) Updated Instructions to: Benadryl elixir-Hydrocortisone-Nystatin susp-Viscous Lidocaine-Maalox or Mylanta. Shake well before use.
Pembrolizumab IV	New Instructions available: Dilute with NS or D5W to a final concentration of 1-10 mg/mL. Infuse with low protein binding filter (0.2 – 5 micron). Do not mix with other drugs. Do not shake. New SIG available: 200 mg intravenously once (Admix: 0.9% Sodium Chloride 100 mL)
Sapanisertib invest Oral	Instructions updated: removed “Take with food.” Removed SIGs: 0 mg/kg orally As Directed 0 mg/m2 orally As Directed

Regimen Library

Additions

Regimen Name	Diagnosis
Breyanzi (Lisocabtagene Maraleucel IV)	Leukemia, Chronic Lymphocytic (CLL); Lymphoma, Non-Hodgkin (NHL) (Parent)
Goserelin Q28D (Breast)	Breast Cancer

 

Updates

Jobevne (bevacizumab-nwgd)

Jobevne (bevacizumab-nwgd) has been added to all bevacizumab‑containing regimens as an un‑prechecked option.

Regimens for the following diagnoses have been updated based on the Collaborative Care Committee voting. Changes include but are not limited to reference updates, drug infusion instruction updates, renaming regimens, premedication template updates, and number of cycles.

• All Problems
• Anal Cancer (Parent)
• Bladder Cancer
• Brain Tumor (Parent)
• Cervical Cancer
• ​Colon Cancer
• Esophageal Cancer (Parent)
• Gastric Cancer
• Head and Neck Cancer (Parent)
• Lung Cancer, Non-small Cell (NSCLC)
• Lung Cancer, Small Cell (SCLC)
• Multiple Myeloma (MM)
• Rectal Cancer
• Renal Pelvis and Ureter Cancer
• Urethral Cancer

Renames

Previous Name	New Name
Docetaxel D1,8,15,22 Q35D	Docetaxel D1,8,15,22 Q28D
Linvoseltamab-gcpt (Lynozyfic) Q7D fb Q14D fb Q28D Maintenance	Linvoseltamab (Lynozyfic) Q7D fb Q14D fb Q28D Maintenance

Removals

Regimen Name	Diagnosis
Cisplatin + Irinotecan D1,8,15 Q28D (Ovarian)	​​Ovarian and Primary Peritoneal Cancer; Fallopian Tube Cancer​
Selinexor D1,3,8,10,15,17,22,24 Q28D	Lymphoma, Non-Hodgkin (NHL) (Parent)

Billing & HCPCS Codes

Additions

Medication	HCPCS Codes
Atropine IM Pen Injector	J3490 per 2 mg
Botulism Immune Globulin, Hum IV	J3590 per: 100 mg 2 mL
Brodalumab Subcutaneous	J3590 per 210 mg
Dexmedetomidine Intranasal	J3490 per 1000 mcg
Dexmedetomidine IV	J3490 per 1000 mcg
Dexmedetomidine Perineural	J3490 per 1000 mcg
Dupilumab Subcutaneous	J3590 per 300 mg
Dupilumab Subcutaneous Pen Injector	J3590 per 300 mg
Elapegademase-lvlr IM	J3590 per 2.4 mg
Epinephrine IM	J3490 per 0.3 mg
Epinephrine IM Pen Injector 0.15 mg/0.15 mL (1:1,000) (Ped)	J3490 per 0.15 mg
Epinephrine IM Pen Injector 0.15 mg/0.3 mL (1:2,000) (Ped)	J3490 per 0.15 mg
Epinephrine IM Pen Injector (Adult)	J3490 per 0.3 mg
Epinephrine Subcutaneous Pen Injector 0.15 mg/0.15 mL (1:1,000) (Ped)	J3490 per 0.15 mg
Epinephrine Subcutaneous Pen Injector 0.15 mg/0.3 mL (1:2,000) (Ped)	J3490 per 0.15 mg
Epinephrine Subcutaneous Pen Injector (Adult)	J3490 per 0.3 mg
eplontersen Subcutaneous	J3490 per 45 mg
Evolocumab Subcutaneous	J3590 per 140 mg
fibrinogen, human-chmt IV	J3590 per 1000 mg
iohexol Epidural 240 mg iodine/mL	Q9966 per 1 mL
ioflupane I IV	A9584 per: 185 MBq 5 mCi
Ketamine Continuous Subcutaneous Infusion	J3490 per 1000 mg/hour
Ketamine Intranasal	J3490 per 1000 mg
Ketamine Oral	J3490 per 1000 mg
Letermovir IV	J3490 per 480 mg
PrabotulinumtoxinA-xvfs IM (cosmetic)	J3590 per: 100 unit 2.5 mL
Pegvaliase-pqpz Subcutaneous	J3590 per 20 mg
Sugammadex IV	J3490 per 500 mg